Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)-Reference-Cited by-同舟云学术

Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)

Published:2022-09 Issue: Volume:173 Page:210-218
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Higashiyama Takuya,Sugino Kiminori^ORCID,Hara Hisato,Ito Ken-ichi,Nakashima Noriaki,Onoda Naoyoshi^ORCID,Tori Masayuki^ORCID,Katoh Hiroshi^ORCID,Kiyota Naomi,Ota Ichiro,Suganuma Nobuyasu^ORCID,Hibi Yatsuka,Nemoto Toshimitsu^ORCID,Takahashi Shunji,Yane Katsunari,Ioji Tetsuya,Kojima Shinsuke,Kaneda Hideaki,Sugitani Iwao^ORCID,Tahara Makoto^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients;Sugitani;World J Surg,2012

2. Management of anaplastic thyroid carcinoma: the fruits from the ATC research Consortium of Japan;Sugitani;J Nippon Med Sch,2018

3. The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study;Onoda;Thyroid,2016

4. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition;Matsui;Int J Cancer,2008

5. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models;Okamoto;Cancer Lett,2013

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of antiangiogenesis tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: A meta-analysis of prospective studies;Medicine;2024-08-02

2. Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer;International Journal of Clinical Oncology;2024-07-23

3. Recent Trends and Potential of Radiotherapy in the Treatment of Anaplastic Thyroid Cancer;Biomedicines;2024-06-10

4. Comprehensive genomic profiling from C‐CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1;Clinical Endocrinology;2024-06-09

5. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan;Thyroid®;2024-03-14